Share with your friends

Opportunities for efficiency in R&D

Opportunities for efficiency in R&D

Most firms face a challenge of improving returns on investment in pharma R&D. Hasini Wijesuriya explains how they can achieve enhanced R&D efficiency.

Hilary Thomas

Director and Chief Medical Adviser



Also on

Opportunities for efficiency in R&D- microscope

Dr. Hasini Wijesuriya, Associate Director and Engagement Manager, Life Sciences Strategy Group and Prof. Hilary Thomas, Chief Medical Adviser, explains that new ways of understanding patients, their behaviour and their optimum outcomes might unlock a new era of R&D efficiency:

  • We’re entering a new phase driven by: patients’ self-articulated needs; new availability of data about their lifestyles; and the evolution of both payer and regulator expectations.
  • New technologies make it easier to address varied patient inputs, rather than snapshots from ‘expert’ or ‘professional’ patients;
  • Pharma firms that can react by placing patients fully at the heart of the R&D process should reap not only benefits for the people being treated – but also better return on investment on their processes and improved investor relations.

Find out more details by downloading our insight exploring the opportunities for efficiency in R&D.

© 2020 KPMG LLP, a UK limited liability partnership, and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. All rights reserved.

KPMG International Cooperative (“KPMG International”) is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.

Connect with us


Want to do business with KPMG?


loading image Request for proposal